Skip to main content
Subscribe
  • Login
  • My Account
  • Logout
  • Register For Free
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Blogs
    • AI
    • Deals
    • Layoff Tracker
    • HLTH 2024
    • Sponsored Content: Vital Signs Blog
  • Opinion
    • Letters
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • 40 Under 40
    • Best Places to Work in Healthcare
    • Healthcare Marketing Impact Awards
    • Innovators Awards
    • Diversity Leaders
    • Leading Women
    • Best in Business Awards
    • The 2030 Playbook Conference
    • Innovations in Patient Experience
    • Leading Women Conference & Awards Luncheon
    • Leadership Summit
    • Workforce Summit
    • Best Places to Work Awards Gala
    • Diversity Leaders Gala
    • - Looking Ahead to 2025
    • - Financial Growth
    • - Hospital of the Future
    • - Value Based Care
    • - Looking Ahead to 2026
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Sponsored Video Series - One on One
    • Sponsored Video Series - Checking In with Dan Peres
  • Data & Insights
    • Data & Insights Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Skilled Nursing Facilities
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
    • Sponsored Content
MENU
Breadcrumb
  1. Home
  2. Technology
December 14, 2015 11:00 PM

Industry-funded studies rise as federally funded studies dip

Sabriya Rice
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    A new study shows that while clinical research funded by industry groups is growing at a fast clip, research paid for by the government is dropping. Findings published Tuesday in JAMA show that between 2006 and 2014, the number of trials paid for by industry rose 43% while those funded by the National Institutes of Health dropped 24%.

    Researchers say industry-sponsored trials concentrate on commercial purposes, while independent studies better inform the public by comparing those products with existing alternatives, like other drugs and lifestyle or dietary interventions.

    “Those kinds of trials are not typically funded by industry,” said study co-author Dr. Stephan Ehrhardt, associate professor in the Johns Hopkins Bloomberg School of Public Health. “But they really inform the health of the public, and answer more than 'does a drug work, yes or no?' ”

    Trials conducted by for-profit organizations are also more likely to only report positive outcomes. Lastly, the findings speak to other ongoing criticisms about the costs, review process and other limitations of clinical research in the U.S.

    Of 18,400 trials registered in 2014 on clinicaltrials.gov, the federal registry and results database of clinical studies involving human participants, more than a third were sponsored by drug or device manufacturers, according to findings.

    There has been mounting concern by patient safety advocates over the past decade that too often adverse events are under-reported by researchers. That issue was tackled by the National Academy of Medicine in January when the group issued four recommendations to address practices that left relevant medical research unpublished. Independent researchers wishing to make comparisons said they couldn't access important and relevant data.

    But the “failing to report” problem is not just limited to industry. A STAT news investigation published this week found some of the worst offenders included academic institutions that are top recipients of NIH funding.

    The 21st Century Cures Act, recently passed by the House, added a new element of worry. The bill would provide an additional $9.3 billion over the next five years to fund the NIH and support breakthroughs in biomedical research, and allow the agency to speed up the review and market approval of breakthrough drugs. Critics worry, however, that the bill relies too heavily on post-market surveillance for flagging adverse events, a system that has proven to be ineffective.

    In the meantime, the number of newly registered trials on the government's clinical trial database has doubled over the past decade. The research letter posted Tuesday in JAMA found that the number rose from 9,321 in 2006.

    “There is now more competition for limited dollars,” said Ehrhardt. “That leaves less space for these relatively important trials that inform public health.”

    The authors also evaluated whether during the time that the NIH funded fewer studies, the agency had become more selective in terms of the size and scope of the limited studies selected. They looked at the median sample size of NIH funded trials across the years and found no difference.

    The NIH agreed that budget constraints in part explain the decline, but also said it has been proactive in figuring out ways to make trials faster, better and less expensive.

    According to a 2014 report from HHS' Office of the Assistant Secretary for Planning and Evaluation, cost is one of the major obstacles to conducting clinical trials in the U.S. The estimated cost of bringing a new drug to market can range from $161 million to $2 billion.

    “What we are after is an ecosystem in which we can fund more high-impact, cost-effective trials,” said Dr. Michael Lauer, NIH deputy director for extramural research via e-mail.

    It's not just about raw counts of trials, but other deeper measures of investment and impact, he said. “We think about costs, cost per patient enrolled, speed of completion and publication, rate of dissemination, and impact on practice and policy.”

    The agency says it offers funding opportunities for low-cost, pragmatic, patient-centered randomized controlled intervention trials and is also an active partner in the Patient-Centered Outcomes Research Institute.

    PCORI, an independent organization created through a provision of the Affordable Care Act, supports research that assesses which healthcare interventions are most effective. Since it launched in 2012, the institute says it has approved $1.18 billion in funding for 468 patient-centered outcomes research projects.

    The studies it funds look at both patient and stakeholder engagement, and offer comparisons of therapies of all kinds, including drugs, devices, lifestyle interventions, care delivery models, surgical procedures and behavioral health therapies. However, the group has been criticized because the funding program does not support applications to conduct studies of cost-effectiveness.

    Ehrhardt says questions about what to research reveal another concern: What ultimately constitutes a good study in the first place? He agrees with concerns raised by ethics researchers and others in a recent Modern Healthcare report highlighting potential problems in the research review process. “We don't even know what a good ethical review is; we don't have quality criteria,” he said.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    IU Health Methodist
    IU Health patient data compromised in cyberattack
    U.S. Food and Drug Administration (FDA)
    Upcoming FDA draft on pulse oximetry's racial bias draws questions
    Most Popular
    1
    New York-Presbyterian layoffs affect 2% of employees
    2
    Here are new state healthcare laws taking effect in 2025
    3
    Meet Modern Healthcare's 2025 Leading Women
    4
    Evernorth, Optum, CenterWell units buoyed insurers in Q1
    5
    What would Medicaid cuts look like? Missouri gave a preview
    Sponsored Content
    Digital Health Intelligence Newsletter: Sign up to receive a twice-weekly (T, F) morning newsletter featuring the latest reporting on technologies, trends, players and money fueling the rapid changes in how healthcare is developed, paid for and delivered.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Help Center
    • Advertise with Us
    • Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2025. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Blogs
      • AI
      • Deals
      • Layoff Tracker
      • HLTH 2024
      • Sponsored Content: Vital Signs Blog
    • Opinion
      • Letters
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • 40 Under 40
        • Best Places to Work in Healthcare
        • Healthcare Marketing Impact Awards
        • Innovators Awards
        • Diversity Leaders
        • Leading Women
        • Best in Business Awards
      • Conferences
        • The 2030 Playbook Conference
        • Innovations in Patient Experience
        • Leading Women Conference & Awards Luncheon
        • Leadership Summit
        • Workforce Summit
      • Galas
        • Best Places to Work Awards Gala
        • Diversity Leaders Gala
      • Virtual Briefings
        • - Looking Ahead to 2025
        • - Financial Growth
        • - Hospital of the Future
        • - Value Based Care
        • - Looking Ahead to 2026
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Sponsored Video Series - One on One
      • Sponsored Video Series - Checking In with Dan Peres
    • Data & Insights
      • Data & Insights Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Skilled Nursing Facilities
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing
      • Sponsored Content